JCSMR School Seminar Series: Multi-drug efflux by P-glycoprotein; why has this protein not been stopped yet?

Associate Professor Richard Callaghan, Human Disease and Membrane Transport Laboratory, Research School of Biology, ANU.

Richard Callaghan obtained his BSc and PhD from the University of Melbourne, completing the latter in 1990. His PhD project investigated the relative preservation of Phase II drug metabolism in liver disease. He then set sails for Canada to undertake post-doctoral studies at McMaster University in Hamilton and subsequently, the University of Toronto. His research investigated the influence of the lipid environment on multidrug resistance conferred by drug transporters. In 1993 he flew across the pond to the UK to undertake post-doctoral studies at the University of Oxford. His research continued to focus on multidrug transporters and their involvement in chemotherapy resistance in cancer. In 1997, he was appointed as a Lecturer in Clinical Biochemistry and a Tutor at Merton College at the University of Oxford. He headed the Oxford Drug Resistance Group and in 2010 made the fateful decision to get some sun during a sabbatical period in Sydney. He subsequently left the dreaming spires for The Australian National University in 2012. After considerable bureaucracy and frustration, his team has now settled into the Research School of Biology. He is pleased to indicate that the Human Disease and Membrane Transport Laboratory is open for business!

Date & time

12–1pm 12 July 2013


The Finkel Lecture Theatre, The John Curtin School of Medical Research, Building 131, Garran Road, ANU


 Laura Vitler, Host: Anna Cowan/Chris Parish
 02 6125 2589

Updated:  24 September 2018/Responsible Officer:  Director, JCSMR/Page Contact:  Web Manager